Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/132743
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Galvan Ruiz, Mario | en_US |
dc.contributor.author | Fernández de Sanmamed Girón, M. | en_US |
dc.contributor.author | Del Val Groba, Marco M. | en_US |
dc.contributor.author | Rojo Jorge, Lorena | en_US |
dc.contributor.author | Peña Saavedra, Claudia | en_US |
dc.contributor.author | Martín Bou, Elvira | en_US |
dc.contributor.author | Andrade Guerra, Ruben | en_US |
dc.contributor.author | Caballero Dorta, Eduardo José | en_US |
dc.contributor.author | García Quintana, Antonio | en_US |
dc.date.accessioned | 2024-08-26T12:31:38Z | - |
dc.date.available | 2024-08-26T12:31:38Z | - |
dc.date.issued | 2024 | en_US |
dc.identifier.issn | 2055-5822 | en_US |
dc.identifier.other | WoS | - |
dc.identifier.other | Scopus | - |
dc.identifier.uri | http://hdl.handle.net/10553/132743 | - |
dc.description.abstract | Aims: The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real-world cohort of patients with heart failure with reduced ejection fraction (HFrEF). Methods: This study is a prospective and observational cohort study of patients with HFrEF and recent HF worsening episodes requiring intravenous therapy who initiated vericiguat in an HF outpatient clinic. A subanalysis of patients with >= 6 months' follow-up was performed separately. Results: Out of 103 patients initially included, 52 had a follow-up of at least 6 months (median follow-up of 303 days). At baseline, the mean age was 71.3 +/- 9.4 years, 27.2% were women, the median left ventricular ejection fraction was 34% (28%-39%) and 99% were taking beta-blockers, 96.1% sodium-glucose cotransporter-2 (SGLT2) inhibitors, 95.1% sacubitril-valsartan, 90.3% aldosterone antagonists and 93.2% loop diuretics. During follow-up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P < 0.001), as did the EuroQol-5D (EQ-5D) and visual analogue scale (VAS) scores (from 0.83 +/- 0.13 to 0.87 +/- 0.12, P = 0.032, and from 60 to 79, P = 0.005, respectively). Vericiguat was well tolerated (13.5% had symptomatic hypotension, and 11.5% had discontinued treatment), and 78.8% of patients achieved the target dose of 10 mg. The number of HF-related hospitalizations/decompensations within the previous 12 months was 2.3 +/- 1.4 and decreased with vericiguat to 0.79 +/- 1.14 (P < 0.001). At study end, 7.7% died (50% for HF). Conclusions: In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | ESC heart failure | en_US |
dc.source | ESC Heart Failure[EISSN 2055-5822], (Enero 2024) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320501 Cardiología | en_US |
dc.subject.other | Heart-Failure | en_US |
dc.subject.other | Heart Failure | en_US |
dc.subject.other | Hospitalization | en_US |
dc.subject.other | Vericiguat | en_US |
dc.title | Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1002/ehf2.15032 | en_US |
dc.identifier.scopus | 85201316163 | - |
dc.identifier.isi | 001292963400001 | - |
dc.contributor.orcid | 0000-0002-7817-5850 | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.orcid | NO DATA | - |
dc.contributor.authorscopusid | 57210104862 | - |
dc.contributor.authorscopusid | 57210110617 | - |
dc.contributor.authorscopusid | 45961185800 | - |
dc.contributor.authorscopusid | 59261191300 | - |
dc.contributor.authorscopusid | 59261548800 | - |
dc.contributor.authorscopusid | 59260833100 | - |
dc.contributor.authorscopusid | 59261735200 | - |
dc.contributor.authorscopusid | 56845776500 | - |
dc.contributor.authorscopusid | 55985523200 | - |
dc.identifier.eissn | 2055-5822 | - |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.contributor.daisngid | No ID | - |
dc.description.numberofpages | 9 | en_US |
dc.utils.revision | Sí | en_US |
dc.contributor.wosstandard | WOS:Ruiz, MG | - |
dc.contributor.wosstandard | WOS:Girón, MFD | - |
dc.contributor.wosstandard | WOS:Marco, MDG | - |
dc.contributor.wosstandard | WOS:Jorge, LR | - |
dc.contributor.wosstandard | WOS:Saavedra, CP | - |
dc.contributor.wosstandard | WOS:Bou, EM | - |
dc.contributor.wosstandard | WOS:Guerra, RA | - |
dc.contributor.wosstandard | WOS:Dorta, EC | - |
dc.contributor.wosstandard | WOS:Quintana, AG | - |
dc.date.coverdate | Enero 2024 | en_US |
dc.identifier.ulpgc | No | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 1,425 | - |
dc.description.jcr | 3,2 | - |
dc.description.sjrq | Q1 | - |
dc.description.jcrq | Q2 | - |
dc.description.scie | SCIE | - |
dc.description.miaricds | 10,3 | - |
item.fulltext | Con texto completo | - |
item.grantfulltext | open | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.fullName | Caballero Dorta, Eduardo José | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
1
checked on Mar 30, 2025
Page view(s)
33
checked on Jan 11, 2025
Download(s)
77
checked on Jan 11, 2025
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.